Ohta A, Takahashi H, Miyata N, Hirono H, Nishio T, Uchino E, Yamada K, Aoyagi Y, Suwabe Y, Fujitake M, Suzuki T, Okamoto K
Tokyo University of Pharmacy and Life Science, Japan.
Biol Pharm Bull. 1997 Oct;20(10):1076-81. doi: 10.1248/bpb.20.1076.
This report describes the anti-platelet aggregation activity of 48 pyrazines. Among alkyl- and arylpyrazines tested, 2,3-diphenylpyrazines showed the strongest anti-platelet aggregation activity. Then, various substituents were introduced into the phenyl groups, and the 2,3-bis(p-methoxyphenyl)pyrazine derivatives were consequently found to possess considerably strong inhibitory activity.